Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

365 ARTÍCULOS , VIENDO DEL 226 AL 240

Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial

Wessels AM, Pollock BG, Anyama NG, Schneider LS, Lieberman JA, Marder SR, Bies RR.

J Clin Psychopharmacol. 2010 Dec;30(6):683-7. doi: 10.1097/jcp.0b013e3181fa05bb.

Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer's disease treatment

Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K.

Molecules. 2010 Dec 2;15(12):8804-12. doi: 10.3390/molecules15128804.

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease

Grossberg GT, Schmitt FA, Meng X, Tekin S, Olin J.

Am J Alzheimers Dis Other Demen. 2010 Dec;25(8):627-33. doi: 10.1177/1533317510385808.

Insulin-resistant brain state (IRBS) changes membrane composition of fatty acids in temporal and entorhinal brain cortices of rats: relevance to sporadic Alzheimer's disease?

Plaschke K, Müller D, Hoyer S.

J Neural Transm (Vienna). 2010 Dec;117(12):1419-22. doi: 10.1007/s00702-010-0523-3. Epub 2010 Dec 7.

Targeting amyloid precursor protein secretases: Alzheimer's disease and beyond

Ganjei JK.

Drug News Perspect. 2010 Nov;23(9):573-84. doi: 10.1358/dnp.2010.23.9.1507297.

Short-term effect of combined drug therapy and cognitive stimulation therapy on the cognitive function of Alzheimer's disease

Matsuda O, Shido E, Hashikai A, Shibuya H, Kouno M, Hara C, Saito M.

Psychogeriatrics. 2010 Dec;10(4):167-72. doi: 10.1111/j.1479-8301.2010.00335.x.

Ginkgo biloba in Alzheimer's disease: a systematic review

Janssen IM, Sturtz S, Skipka G, Zentner A, Velasco Garrido M, Busse R.

Wien Med Wochenschr. 2010 Dec;160(21-22):539-46. doi: 10.1007/s10354-010-0844-8.

Fixing Alzheimer disease trials by improving process and methods

Schneider LS.

Curr Alzheimer Res. 2010 Nov;7(7):564-5. doi: 10.2174/156720510793498995.

Neuroprotective role for galanin in Alzheimer's disease

Counts SE, Perez SE, Ginsberg SD, Mufson EJ.

Exp Suppl. 2010;102:143-62. doi: 10.1007/978-3-0346-0228-0_11.

Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease

Isik AT, Bozoglu E, Naharci MI, Kilic S.

Am J Geriatr Pharmacother. 2010 Oct;8(5):454-9. doi: 10.1016/j.amjopharm.2010.09.001.

A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors

Jones RW.

Int J Geriatr Psychiatry. 2010 Jun;25(6):547-53. doi: 10.1002/gps.2384.

Pharmacological treatment of Alzheimer's disease: effect of race and demographic variables

Hernandez S, McClendon MJ, Zhou XH, Sachs M, Lerner AJ.

J Alzheimers Dis. 2010;19(2):665-72. doi: 10.3233/JAD-2010-1269.

Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence

Szekely CA, Zandi PP.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):132-9. doi: 10.2174/187152710791012026.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias